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Marissa Suarez2,3, John Guatelli2,3*, Yong Xiong1*
1Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, 
United States; 2Department of Medicine, University of California San Diego, La Jolla, 
United States; 3The VA San Diego Healthcare System, San Diego, United States
Abstract BST2/tetherin, an antiviral restriction factor, inhibits the release of enveloped viruses 
from the cell surface. Human immunodeficiency virus-1 (HIV-1) antagonizes BST2 through viral 
protein u (Vpu), which downregulates BST2 from the cell surface. We report the crystal structure of 
a protein complex containing Vpu and BST2 cytoplasmic domains and the core of the clathrin 
adaptor protein complex 1 (AP1). This, together with our biochemical and functional validations, 
reveals how Vpu hijacks the AP1-dependent membrane trafficking pathways to mistraffick BST2. 
Vpu mimics a canonical acidic dileucine-sorting motif to bind AP1 in the cytosol, while simultaneously 
interacting with BST2 in the membrane. These interactions enable Vpu to build on an intrinsic 
interaction between BST2 and AP1, presumably causing the observed retention of BST2 in 
juxtanuclear endosomes and stimulating its degradation in lysosomes. The ability of Vpu to hijack 
AP-dependent trafficking pathways suggests a potential common theme for Vpu-mediated 
downregulation of host proteins.
DOI: 10.7554/eLife.02362.001
Introduction
The interferon-inducible restriction factor BST2 (also named tetherin, CD317 and HM1.24) presents a 
potent innate immune restriction to many enveloped viruses (Neil et al., 2008; Van Damme et al., 
2008; Jouvenet et al., 2009; Evans et al., 2010; Arias et al., 2012). BST2 has a short cytoplasmic tail 
at the N-terminus followed by a single transmembrane (TM) helix, a long coiled-coil extracellular 
domain, and a C-terminal glycosyl phosphatidylinositol (GPI) anchor (Kupzig et al., 2003). The availa-
bility of two membrane anchors connected by a long coiled-coil allows BST2 to efficiently inhibit viral 
transmission by tethering newly formed virions at the infected cell surface and preventing their release 
to the surrounding environment (Hinz et al., 2010; Schubert et al., 2010; Yang et al., 2010). The 
short intracellular, N-terminal tail of BST2 has been implicated in the natural trafficking of this antiviral 
protein (Rollason et al., 2007; Masuyama et al., 2009).
HIV-1 overcomes restriction by BST2 using the viral protein Vpu (Neil et al., 2008; Van Damme et al., 
2008). The mechanism by which Vpu antagonizes BST2 appears to be multifaceted, involving both degra-
dation and mistrafficking within the endosomal system. Vpu (about 81 amino acids in most viral isolates) is 
a transmembrane protein consisting of an N-terminal transmembrane α-helix, followed by a cytoplasmic 
domain that is likely to be flexible (Cohen et al., 1988; Strebel et al., 1988). Vpu associates with BST2 
through an anti-parallel interaction between the transmembrane domains of each protein (Mangeat et al., 
2009; Skasko et al., 2012; McNatt et al., 2009; Vigan and Neil, 2011; Kobayashi et al., 2011; Vigan 
and Neil, 2010). This interaction is species-specific and essential for the antagonism of BST2 by Vpu 
(McNatt et al., 2009; Skasko et al., 2012). Part of Vpu's activity against BST2 can be explained by the viral 
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hijacking of the β-TrCP-associated ubiquitin–proteasome degradation pathway (Van Damme et al., 2008; 
Douglas et al., 2009; Goffinet et al., 2009; Iwabu et al., 2009; Mangeat et al., 2009; Mitchell et al., 
2009). A component of the ESCRT-0 machinery, HRS, has also been suggested to recognize ubiquitinated 
BST2 and target it for lysosomal degradation (Janvier et al., 2011). However, these degradation pathways 
are only partially responsible for the antagonism of BST2 by Vpu (Van Damme et al., 2008; Douglas et al., 
2009; Iwabu et al., 2009; Mangeat et al., 2009; Mitchell et al., 2009). Efficient BST2 downregulation 
from the cell surface can occur in the absence of BST2 degradation (Dube et al., 2010; Goffinet et al., 
2010; Tervo et al., 2011). Moreover, Vpu induces the mistrafficking of BST2 (Douglas et al., 2009; Dube 
et al., 2010; Hauser et al., 2010; Lau et al., 2011; Schmidt et al., 2011), causing the accumulation of 
BST2 at the trans-Golgi network (TGN). Both recycled and newly synthesized BST2 are retained at the 
TGN, blocking the resupply of BST2 to the plasma membrane and eventually leading to its depletion at the 
cell surface (Dube et al., 2011; Lau et al., 2011; Schmidt et al., 2011). Moreover, mutations in the juxta-
membrane hinge region of Vpu that interfere with the localization of Vpu to the TGN impair the antago-
nism of BST2 (Dube et al., 2009; Vigan and Neil, 2011).
Clathrin-dependent trafficking pathways have been suggested to be involved in the Vpu-mediated 
mistrafficking of BST2 (Kueck and Neil, 2012; Lau et al., 2011; Mitchell et al., 2009; Ruiz et al., 2008). 
Such pathways regulate the trafficking of cellular membrane proteins by selectively packaging these mem-
brane cargos into clathrin-coated vesicles (CCV) (Bonifacino and Traub, 2003; Canagarajah et al., 2013; 
Traub, 2009). The clathrin adaptor protein (AP) complexes mediate this cargo selection. Two canonical 
sorting motifs in the cytoplasmic domains of the membrane cargo proteins are recognized by the AP com-
plexes: a tyrosine-based Yxxϕ motif (ϕ represents a large hydrophobic residue; x for any amino acid) and 
an acidic dileucine motif, [E/D]xxxL[L/I]. Five AP complexes exist in the cell and each is responsible for traf-
ficking by distinct routes. For example, AP1 traffics cargo between the TGN and sorting endosomes, while 
AP2 selects cargo for transport between the plasma membrane and early endosomes (Canagarajah et al., 
2013). In the absence of Vpu, the natural trafficking of endogenous BST2 depends on the clathrin-
associated pathways, and the involvement of both AP1 and AP2 has been suggested (Rollason et al., 
2007; Masuyama et al., 2009). An unusual double-tyrosine motif, YxY, in the BST2 cytoplasmic domain 
(BST2CD) is critical for this natural trafficking (Rollason et al., 2007; Masuyama et al., 2009). In Vpu, a 
putative clathrin-sorting motif, ExxxLV (ELV), located in the membrane-distal half of the protein's cytoplas-
mic domain (VpuCD) was shown to be important for BST2 antagonism (Kueck and Neil, 2012, McNatt 
et al., 2013). Furthermore, Vpu-induced virion release and removal of BST2 from the cell surface are 
inhibited by a dominant negative mutant of AP180, a protein required for the assembly of the CCV at 
the lipid membrane (Kueck and Neil, 2012; Lau et al., 2011). However, the critical question remains 
as to whether any AP complexes, and if so which, are hijacked by Vpu for the downregulation of BST2.
eLife digest HIV is a retrovirus that attacks the immune system, making the body increasingly 
susceptible to opportunistic infections and disease and eventually leading to AIDS. While antiretroviral 
drugs have allowed people with AIDS to live longer, there is no cure or vaccine for HIV.
Two types of HIV exist, with HIV-1 being much more common and pathogenic than HIV-2. Like other 
‘complex’ retroviruses, the HIV-1 genome contains genes that encode various proteins that allow the 
virus to disrupt the immune response of the host it is attacking. Viral protein u is a protein encoded by 
HIV-1 (but not HIV-2) that counteracts an antiviral protein called BST2 in the host. BST2, which is part of 
the host's innate immune response, prevents newly formed viruses from leaving the surface of infected 
cells. By counteracting BST2, viral protein u allows the virus to spread in the host more efficiently.
Like many proteins, newly produced BST2 is packaged inside structures called vesicles in a part 
of the cell called the trans-Golgi network, and then sent to its destination. Complexes formed by 
various proteins make sure that the vesicles take their cargo to their correct destinations within the 
cell. Two adaptor protein complexes—known as AP1 and AP2—are thought to be involved the 
transport of BST2. However, it is not known how viral protein u stops BST2 from reaching the cell 
surface, or how it decreases the amount of BST2 in the cell as a whole. Jia et al. show how viral 
protein u and BST2 jointly interact with AP1. This interaction leads to the mistrafficking and 
degradation of BST2 and the counteraction of its antiviral activity.
DOI: 10.7554/eLife.02362.002
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To understand the mechanisms of Vpu-mediated mistrafficking of BST2, we examined the interac-
tion of the cytoplasmic domains of these proteins with recombinant AP complexes and their subunits. 
Moreover, we determined the crystal structure of a three-component complex containing AP1, the 
cytoplasmic domain of BST2 (BST2CD) and the cytoplasmic domain of Vpu (VpuCD). The structure shows 
that Vpu mimics a membrane cargo by occupying the acidic dileucine-binding site of AP1, while BST2 
is bound at the tyrosine-binding site of AP1. This, together with biochemical and functional evidence, 
suggests that HIV-1 Vpu is a virally encoded modulator of clathrin-dependent trafficking pathways and 
supports the involvement of AP1 in the Vpu-mediated mistrafficking of BST2.
Results
BST2 specifically binds μ1 of AP1, but not μ2 of AP2 or μ3 of AP3
To identify the AP complexes involved in the trafficking of BST2, we investigated their ability to bind 
BST2. BST2CD contains a putative tyrosine motif that is believed to bind to the μ subunits of AP com-
plexes, and intracellular interactions between BST2 and the μ subunits of either AP1 or AP2 have been 
reported (Rollason et al., 2007; Masuyama et al., 2009). We tested interactions between BST2CD and 
the C-terminal domains (CTD) of the μ subunits of three AP complexes (AP1, AP2, and AP3). The puri-
fied μ1-CTD of AP1 bound BST2CD as the two co-migrated as a higher molecular weight complex on a 
size exclusion column (Figure 1A). In contrast, no such binding was observed for either the μ2-CTD 
Figure 1. BST2 interacts with µ1 but not µ2 or µ3. (A–C) Size exclusion chromatograms and SDS PAGE analysis of 
purified MBP-BST2CD (purple curve), MBP-µ CTD (green curve), and their mixture (red curve). A MBP-µ1 CTD and 
MBP-BST2CD complex is formed in (A), as indicated by the shift (P1) of its elution volume from those of the individual 
components (P2 and P3). No complex formed between BST2 and µ2 (B) or µ3 (C). (D) Yeast 2-hybrid assays showing 
binding of BST2CD to µ1, but not µ2 or µ3. Growth on -Leu/-Trp/-His + 3 mM 3AT plates indicates interaction. 
Growth on -Leu/-Trp serves as a growth control. ‘0.5x’ indicates plating of one-half the amount of yeast cells relative 
to other spots. The BST2CD-µ1 interaction is abolished by the tyrosine motif mutation Y6/8A in BST2CD or the tyrosine-
binding pocket mutation D174A in µ1.
DOI: 10.7554/eLife.02362.003
The following figure supplements are available for figure 1:
Figure supplement 1. BST2 does not interact with the α appendage domain of AP2. 
DOI: 10.7554/eLife.02362.004
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(Figure 1B) or μ3-CTD (Figure 1C). These observations were further confirmed by a yeast two-hybrid 
(Y2H) assay (Figure 1D). Consistent with the in vitro binding assay, BST2CD exhibited binding to μ1, but 
not μ2 or μ3, in the Y2H assay. As controls, the TGN38 peptide containing a canonical YxxΦ motif 
displayed binding to all three μ subunits, and a mutant μ1 subunit (μ1 D174A) with a disrupted binding 
pocket for tyrosine-based motifs bound neither TGN38 nor the BST2CD. Furthermore, this binding was 
abolished by the double alanine mutation of the YxY motif (Y6/8A) in BST2CD. These results indicate 
that BST2CD not only contains a tyrosine-based motif to allow for AP binding, but also a specificity 
determinant to select specifically for μ1.
Our results support the involvement of AP1 in trafficking of BST2 and are consistent with a pre-
vious observation that BST2 binds to the μ1 subunit of AP1, but not μ2 of AP2 (Masuyama et al., 
2009). In the absence of Vpu, BST2 has been suggested to localize to the TGN through clathrin-
dependent trafficking (Kupzig et al., 2003; Rollason et al., 2007; Masuyama et al., 2009), and the 
BST2–AP1 interaction may be responsible for this localization. In contrast, an involvement of AP2 in 
BST2 trafficking has been suggested to occur through its α appendage domain. However, this inter-
action was not detected in our in vitro binding test using size exclusion chromatography (Figure 1—
figure supplement 1). A specific site on AP2 for BST2 binding remains to be clearly elucidated.
HIV-1 Vpu binds to multiple subunits of both AP1 and AP2, but not μ3 
of AP3
Given the native affinity of BST2 for AP1 and the retention of BST2 in the TGN by Vpu, we sought to 
define the potential interactions between Vpu and AP1. As the functionally active ELV motif in VpuCD 
is a putative acidic dileucine sorting signal, we hypothesized that Vpu binds AP1 at the acidic dileucine-
binding site located at the γ and σ1 subunits. To test this, we created a truncated AP1 core with the 
μ1-CTD removed. Such a truncation construct (AP1t) mimics the open conformation of AP1, exposing 
the dileucine binding site on AP1 for interaction with cargo (Jackson et al., 2010). We co-expressed 
VpuCD with casein kinase II (CKII) to phosphorylate VpuCD at S52 and S56 to mimic its cellular state 
(Figure 2—figure supplement 1). Unless mentioned otherwise, doubly phosphorylated Vpu constructs 
were used in all in vitro studies. Indeed, MBP-VpuCD co-migrated with the μ1-truncated AP1 as a 
complex on a size exclusion column (Figure 2A). Importantly, the binding was abolished by the 
alanine-mutation of the ELV motif, signifying the crucial role of the ELV motif in the interaction between 
Vpu and AP1 (Figure 2B). We further tested the binding between VpuCD and μ1-CTD and observed 
complex formation using size exclusion chromatography (Figure 2C). These interactions demonstrate 
that Vpu has evolved the ability to associate with multiple subunits of AP1, potentially allowing it 
to modulate the cellular trafficking machinery to target host proteins such as BST2.
We next investigated the interaction between Vpu and subunits of AP2 and AP3. We used size 
exclusion chromatography to test the binding between VpuCD and a truncated hemicomplex of AP2, 
α (1–398)-σ, which contains the binding pocket for the acidic dileucine sorting motif; an interaction 
complex was observed (Figure 2D). Furthermore, binding between VpuCD and the μ2-CTD of AP2 was 
also observed (Figure 2E), while no such binding was observed between VpuCD and the μ3-CTD of 
AP3 (Figure 2F). Altogether, these results suggest specific interactions between Vpu and AP1 and 
AP2, which may allow the viral protein to hijack the associated trafficking pathways. However, because 
BST2CD specifically binds only to μ1, but not to μ2 or μ3 (Figure 1), AP1 may play a more significant 
role than AP2 in the Vpu-mediated antagonism of BST2. This notion is supported by multiple observa-
tions, with one exception (Iwabu et al., 2010), that Vpu does not increase the rate of BST2 internali-
zation from the cell surface (Mitchell et al., 2009; Dube et al., 2010; Andrew et al., 2011; Schmidt 
et al., 2011).
Fusion of BST2CD and VpuCD enhances binding to AP1
The ability of Vpu to interact simultaneously with BST2 and AP1 suggests that Vpu may enhance a 
native but weak affinity between BST2 and AP1 to increase their binding and consequently retain BST2 
in endosomes including the TGN and/or target it to lysosomes. We used a fusion of BST2CD and VpuCD 
to mimic in vitro the membrane-assisted binding that occurs in cells. BST2 and Vpu each have a trans-
membrane (TM) helix through which the two proteins associate. The C-terminus of BST2CD and the 
N-terminus of VpuCD are placed close to each other by the interacting TM helices (Skasko et al., 2012). 
This facilitates the convenient design of a 10-amino acid fusion linker that mimics the restraints exerted 
by the TM helices and links the cytoplasmic domains in an appropriate spatial arrangement (Figure 3A). 
Biophysics and structural biology | Microbiology and infectious disease
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The fusion protein exhibited strong binding to the GST-tagged AP1 in the pulldown assay (Figure 3B). 
In contrast, although both VpuCD and BST2CD interact with AP1 subunits in our size exclusion chroma-
tography assays (Figure 1, Figure 2), their individual interactions with the full AP1 core complex were 
not observed under stringent pulldown conditions (Figure 3B). This result suggests that an additive or 
cooperative effect occurs when BST2CD and VpuCD bind to AP1.
BST2/Vpu/AP1 interaction involves BST2 YxY and the dileucine motif-
binding site on AP1, and is independent of Vpu phosphorylation
We tested the requirement of the important motifs in BST2 and Vpu for the binding of AP1. We first 
used a GST-tagged AP1 core to pull down mutants of the BST2CD-VpuCD fusion (Figure 4). As expected, 
alanine mutation of the YxY motif (Y6/8A) greatly reduced the binding to AP1. Additional mutation of 
the γ subunit R15E on AP1 that disrupts the acidic dileucine-motif binding site affected the binding 
further. To validate the in vitro observations made with the TM-free BST2CD-VpuCD fusion, we designed a 
TM-containing chimera and performed immunoprecipitation experiments using human cells (Figure 4B,C). 
This chimera contains the N-terminal 66 residues of BST2 (including the cytoplasmic domain, TM, and 
Figure 2. Vpu interacts with multiple subunits of AP1 and AP2, but not μ3 of AP3. (A and B) Size exclusion chromatograms and SDS PAGE analysis 
of purified MBP-VpuCD constructs (cyan curve and bottom SDS gel) and its mixture with μ1-truncated AP1 (AP1t) (red curve and top SDS gel). (A) The elution 
profile of MBP-VpuCD on the size exclusion column is altered in the presence of AP1t (marked by the red arrow), indicating complex formation. (B) The 
alanine mutation of the ELV motif in VpuCD (MBP-VpuCD ELV/AAA) abolishes the interaction with AP1t, as the elution profile of MBP-VpuCD ELV/AAA does 
not change with or without AP1t. (C) MBP-VpuCD binds to MBP-µ1 CTD. A shift occurs in the elution volume of the MBP-µ1 CTD and MBP-VpuCD mixture (P1) 
relative to the individual components (P2 and P3). (D) Size exclusion chromatogram and SDS PAGE analysis showing the co-migration of MBP-VpuCD and 
α398-σ to a higher molecular weight region relative to the individual components. (E) MBP-VpuCD and MBP-μ2-CTD also form a co-migrating interaction 
complex. (F) No complex is formed between MBP-VpuCD and MBP-μ3-CTD as the mixture migrates in the same manner as the individual components.
DOI: 10.7554/eLife.02362.005
The following figure supplements are available for figure 2:
Figure supplement 1. Efficient and complete double phosphorylation of recombinant VpuCD. 
DOI: 10.7554/eLife.02362.006
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two of the three cysteines in the ectodomain involved in dimerization) followed by a flexible linker 
(GGGSx3), a FLAG epitope tag, and the entirety of Vpu; we expected it to faithfully recapitulate the 
geometry of the two interacting molecules in cells (Figure 4B). Consistent with the in vitro observa-
tions (Figure 3B), binding between endogenous AP1 (the µ1subunit) and this chimera was detected, 
while no such binding was detected for either BST2 or Vpu alone (Figure 4C). Although the alanine 
mutations of either Y6/8 or ELV did not substantially reduce the binding, the mutant combining both 
sets of mutations was unable to bind AP1 (Figure 4C).
Our experiments show that the binding of Vpu to AP1 is independent of serine-phosphorylation 
(Figure 4A). Phosphorylation of S52 and S56 in Vpu is critical for recruiting β-TrCP and its associated 
E3 ubiquitin ligase complex. The unphosphorylated fusion protein bound AP1 as tightly as the phos-
phorylated construct (Figure 4A). Furthermore, the binding of AP1 was not affected by the double 
mutation, S52/56N, that destroys the phosphorylation sites (Figure 4A). These results are consistent 
with the notion that the β-TrCP-dependent BST2-degradation by Vpu and the mistrafficking of BST2 
by Vpu are governed by different determinants in the VpuCD.
Crystal structure of BST2 and Vpu binding to the open AP1 core
To understand the Vpu-enhanced binding of BST2 to AP1, we determined the crystal structure of the 
BST2CD-VpuCD fusion in complex with the AP1 core at 3.0 Å resolution (Figure 5A). The AP1 core 
adopts an activated, open conformation, with both of its cargo binding sites exposed for interaction 
with BST2CD-VpuCD. The AP1 in the current structure adopts an open conformation distinct from that 
observed previously for AP2 and AP1 (Jackson et al., 2010; Ren et al., 2013). BST2CD binds to the 
tyrosine motif-binding site on AP1 through critical interactions involving the YxY motif, while VpuCD 
occupies the acidic dileucine motif-binding site of AP1 through the ELV motif. Only a short region of 
VpuCD flanking the ELV motif is well ordered and successfully built in the structure. There is no direct 
interaction between BST2CD and VpuCD. Overall, the structure reveals how Vpu enhances the native 
interaction between BST2 and AP1. By combining the viral protein's affinity for AP1 via the ELV motif 
and the tight transmembrane interaction with the host protein, Vpu appears to act as an adaptor to 
increase the affinity of AP1 for BST2.
BST2 binds to AP1 via an unusual YxY motif
BST2CD occupies the conserved tyrosine motif-binding site on the μ1 subunit of AP1 (Figure 5B–D). 
However, the observed interface differs from the canonical tyrosine peptide (YxxΦ) binding in that the 
interaction is achieved with an unusual double-tyrosine motif (YxYxxΦ) (Figure 5B,D). Y8 of BST2CD 
forms the canonical interactions with μ1 residues and inserts into the conserved tyrosine-binding 
Figure 3. BST2CD-VpuCD fusion binds tightly to AP1. (A) Schematic of the BST2–Vpu interaction at the lipid membrane 
(top) and the fusion protein used for in vitro studies (bottom) showing the location of important residues in both 
BST2 (YxY) and Vpu (ELV). S52 and S56 are phosphorylation sites required for the binding of Vpu to β-TrCP. The regions 
of Vpu and BST2 used in the fusion are boxed in green. (B) GST pulldown assay using an AP1 with a GST-tagged γ 
subunit. GST bead-bound AP-1 captured MBP-BST2CD-VpuCD, but not MBP-VpuCD or MBP-BST2CD alone. SDS PAGE 
analysis shows the amount of protein in the load and eluted from the GST beads.
DOI: 10.7554/eLife.02362.007
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pocket on μ1. Unlike the canonical cases in which a leucine or isoleucine residue is found at the Y+3 
position, V11 in BST2 only partly fills the corresponding hydrophobic pocket on μ1 (Figure 5C). This 
pocket would be better satisfied by a larger hydrophobic residue. This observation is consistent with 
results from a previous combinatorial screen of tyrosine-based µ-binding sequences: for µ1, valine was 
disfavored at the Y+3 position, whereas leucine was favored (Ohno et al., 1998). The relatively modest 
interaction mediated by V11 is presumably compensated by Y6, which stabilizes the binding through 
hydrogen-bonding interactions with N308 and E381 of μ1 and through stacking interactions with μ1 
P383 and Y384. Consistent with the notion that Y6, Y8, and V11 each contribute to the overall binding, 
substitution of any of these single residues with alanine was sufficient to disrupt the interaction 
between BST2CD and µ1 as detected using the Y2H assay (Figure 5E).
The structure also explains why BST2, specifically the YxYxxV sequence, has a preference for 
μ1, but not μ2 or μ3 (Figure 1D). An overlay of the BST2CD-bound μ1 structure to the μ2 structure 
shows that μ2 lacks a tyrosine residue, corresponding to μ1 Y384, which provides a stabilizing 
stacking interaction with BST2 Y6 (Figure 5—figure supplement 1A). In addition, the presence of 
μ2 Q318, in place of the smaller N308 of μ1, disrupts a hydrogen-bonding interaction with the side 
chain of BST2 Y6 and potentially causes steric hindrance. In the case of μ3, the structural differ-
ence is much more pronounced: severe steric clashes appear to prevent the binding of BST2 
Y6 (Figure 5—figure supplement 1B). Overall, these results not only explain a critical feature 
of Vpu-mediated hijacking of the AP1-dependent CCV pathway for BST2 antagonism, but also 
serve as the first structural example of a cellular YxY-based sorting signal bound to the μ1 subunit 
of AP1.
Figure 4. BST2/Vpu/AP1 interaction involves the BST2 YxY sequence and the dileucine motif-binding pocket 
on γ/σ1 and is independent of Vpu phosphorylation. (A) GST affinity pulldown assay using an AP1 core complex 
with a GST-tagged γ subunit. Mutation of the acidic dileucine pocket on γ (‘AP1 R15E’) and the YxY motif on 
BST2 substantially reduced binding to AP1. Phosphorylation or S52/56N mutation of Vpu has no effect on AP1 
binding. (B) Schematic of the TM-containing BST2 and Vpu fusion chimera. The broken line indicates the first 
20 residues of the native BST2 ectodomain followed by the fusion linker, the FLAG epitope tag, and the Vpu 
ectodomain. (C) HEK293T cells were transfected to express FLAG-tagged Vpu, BST2, or the fusion chimera or 
related mutants. ‘no FLAG’ indicates mock transfection without any FLAG-tagged construct. Notably, Vpu is 
much more abundantly expressed than either BST2 or the BST2-Vpu chimeras, and the chimeras appear to be 
partly proteolyzed. Nonetheless, immunoprecipitation (IP) using anti-FLAG antibody shows endogenous µ1 
only in the presence of the BST2-Vpu chimera. Mutation of both the BST2 YxY and Vpu ELV motifs is necessary 
to prevent co-IP of µ1.
DOI: 10.7554/eLife.02362.008
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Vpu binds to AP1 by mimicking a canonical acidic dileucine motif
Opposite to the BST2-binding site on the activated AP1 core, VpuCD associates with the γ and σ1 
subunits of AP1 by mimicking the canonical acidic dileucine-sorting motif (Figure 5). E62 forms a salt 
bridge with R15 of AP1 γ subunit, fulfilling the role of the ‘acidic residue’ within the sorting motif, while 
L66 and V67 embed into the hydrophobic pocket on AP1 σ1 that accommodates the canonical dileu-
cine residues (Figure 5F). The Vpu ELV motif overlays closely with a canonical acidic dileucine-sorting 
motif when bound to AP2 (Figure 5G). Our results reveal that the ELV motif of Vpu acts as a sorting 
motif mimic for hijacking AP1 and thus the CCV pathway for mistrafficking of BST2.
A novel open conformation is observed for the BST2/Vpu-activated AP1
While the previously observed Arf1-bound AP1 exhibits the same level of opening as the activated 
AP2 (Jackson et al., 2010; Ren et al., 2013), the AP1 in the BST2/Vpu-bound structure adopts a 
Figure 5. Crystal structure of the BST2CD-VpuCD/AP1 complex. (A) The crystal structure of the BST2CD-VpuCD/AP1 complex. AP1 is colored by subunit (β1 in gray, 
γ in orange, μ1 in green and σ1 in yellow). VpuCD (cyan) binds to the acidic dileucine binding pocket of γ/σ1, and BST2CD (magenta) binds to the tyrosine-binding 
pocket in μ1. (B) The difference Fourier map (mFo-DFc at 3σ level, blue mesh) of BST2CD (magenta sticks) binding to μ1 (green surface). Important residues in 
BST2CD are labeled. (C) V11 partly fills the canonical Φ residue binding-site on µ1. (D) Y6 and Y8 make extensive interactions to µ1 residues. Hydrogen bonds are 
indicated with dashed lines. (E) Yeast 2-hybrid assays showing binding of BST2 to µ1. Growth on -Leu/-Trp/-His + 3 mM 3AT plates indicates interaction. Growth 
on -Leu/-Trp serves as a growth control. ‘0.2x’ indicates plating of one-fifth the amount of yeast cells relative to other spots. The BST2-µ1 interaction is abolished 
by the alanine mutations of BST2 Y6/8A, Y6A, Y8A, or V11A. (F) The difference Fourier map (mFo-DFc at 3σ level, blue mesh) of VpuCD (cyan sticks) binding to σ1 
(yellow surface) and γ (orange surface) subunits of AP1. Important VpuCD and γ residues are labeled. (G) Overlay of α/σ2 of AP-2 (PDB ID 2JKT) (Kelly et al., 
2008) and γ/σ1 of AP1 shows that the Vpu ELV motif (cyan) binds in the same way as the canonical peptide (gray).
DOI: 10.7554/eLife.02362.009
The following figure supplements are available for figure 5:
Figure supplement 1. Structural incompatibility prevents the binding of BST2 to either µ2 of AP2 or µ3 of AP3. 
DOI: 10.7554/eLife.02362.010
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conformation that is much more open than the previously observed structures. When the BST2/Vpu-
activated AP1 structure was overlaid with the Arf1-activated AP1 structure using the β1 subunits, 
a twisting of the γ and σ1 subunits was observed (Figure 6A), which further exposes the dileucine-
binding pocket at the γ/σ1 interface in AP1. The conformational change involves a ∼20° rotation of 
γ/σ1 around an axis at the base of γ where it contacts β1, with the largest Cα movement of ∼35 Å at 
the tip of γ (Figure 6A). Of note, however, the relative positions either between β1 and μ1 or between 
γ and σ1 are well maintained. As a result of the γ/σ1 movement, new interactions occur between the 
μ1-CTD and the N-terminal portion of γ. This new γ–μ1 interface has a buried surface area of 685 Å2, 
and consists of extensive, hydrogen-bonding and salt bridge interactions between the two subunits 
(Figure 6B,C). We further created a double mutation, γ Q28R and μ1 D319R, to disrupt this new inter-
face and tested its role in the binding of AP1 to BST2/Vpu in the GST pulldown assay. The binding was 
decreased, indicating that this newly observed γ–μ1 interface is important for the Vpu-mediated 
manipulation of AP1 (Figure 6D). This new AP1 conformation supports the recent hypothesis that the 
AP complexes might be able to access a wider conformational space beyond what has been previously 
observed in the locked, unlatched, and open states (Canagarajah et al., 2013).
Vpu R44 and L/I45 potentially interact with the μ1 subunit of AP1
The newly formed γ–μ1 interface leads to local structural changes. Specifically, the μ1 loop from P363 
to G372, which is disordered in the previous AP1 structures (Heldwein et al., 2004; Jia et al., 2012; 
Ren et al., 2013), became well ordered in the current structure. Although all of the nearby residues 
from both γ and μ1 are well ordered, considerable additional electron density remains near the γ–μ1 
interface, suggesting the possible presence of Vpu residues (Figure 7A). Although the quality of the 
additional electron density does not permit model building, we suspect it may belong to a portion of 
VpuCD that is N-terminal to the ELV, judging by the location of the electron density relative to Vpu ELV 
(Figure 7A). Specifically, Vpu residues R44 and L45 (NL4-3 sequence, corresponding to I45 of Vpu 
Figure 6. AP1 adopts a novel open conformation when bound to BST2CD and VpuCD. (A) Overlay of the Arf1-bound 
AP1 structure (PDB ID 4HMY, grey surface) (Ren et al., 2013) and the BST2CD-VpuCD-bound AP1 structure (ribbon 
representation with β1 in blue, γ in orange, μ1 in green and σ1 in yellow). The broken arrows point to the large 
relative movement of the γ/σ1 subunits of our structure with respect to Arf-1/AP1. Note that the β1/μ1 subunits 
overlay well in the two structures. (B and C) Close-up views of the new γ-μ1 interface observed in the present study, 
boxed in (A), with hydrogen bonds represented by dashes. (D) GST affinity pulldown assay using an AP1 core complex 
with GST-tagged γ subunit. Mutations at the γ-μ1 interface reduced MBP-BST2CD-VpuCD binding to AP1.
DOI: 10.7554/eLife.02362.011
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Figure 7. Vpu R44, L/I45 residues may interact with AP1 at the γ-μ1 interface and contribute to the optimal Vpu activity. (A) The difference Fourier map 
(mFo-DFc at 3σ level, blue mesh) near γ (orange)-μ1 (green) interface of AP1. VpuCD is shown in cyan sticks and AP1 σ1 is in yellow. (B and C) Affinity pulldown 
assays using an AP1 with GST-tagged γ subunit (B) or using a His-tagged MBP-μ1-CTD (C). SDS PAGE analysis shows the amount of protein in the load and 
elution. Mutation of these potentially important Vpu residues at the γ-μ1 interface, R44A:I45A, significantly affected the binding interactions. (D) Downregulation 
of surface BST2 by Vpu is impaired by the R44A:L45A (RL/AA) mutation as well as by the S52N:S56N (S52/56N) mutation. (E) HEK293T cells were co-transfected 
to express provirus lacking vpu, and the indicated codon-optimized Vpu proteins. The Vpu R44A:L45A and S52N:S56N mutations each impair Vpu mediated-
virion release, and their effects are additive. (F) Western blot of the experiment shown in E, indicating the expression levels of BST2 and Vpu; gp120 is the viral 
envelope glycoprotein. (G) Co-IP showing that β-TrCP binding was abolished by the S52/56N (‘2/6’) mutation, but not the RL/AA mutation.
DOI: 10.7554/eLife.02362.012
The following figure supplements are available for figure 7:
Figure supplement 1. VpuCD exhibits large conformational flexibility. 
DOI: 10.7554/eLife.02362.013
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HV1S1 used in the structural study) upstream of ELV may participate in the interaction with AP1, 
as these conserved residues have been implicated in Vpu-mediated antagonism of BST2 (Lucas and 
Janaka, 2012; Pickering et al., 2014).
We tested the Vpu R44A and I45A double mutation for its effect on the binding to AP1 in vitro. The 
binding was impaired by this mutation (Figure 7B). Specifically, the mutation substantially reduced the 
binding between the BST2CD-VpuCD fusion and μ1-CTD of AP1 in our pulldown assay (Figure 7C). This 
interaction likely explains the observed affinity between Vpu and μ1 (Figure 2C). It also suggests that 
the extra electron density in our structure (Figure 7A) may come from Vpu residues including R44 and 
L/I45. These Vpu residues may interact with γ/μ1 subunits of AP1 and stabilize γ–μ1 contacts and the 
novel AP1 conformation.
We characterized the effect of the R44A:L45A mutation on the activity of Vpu as an antagonist of 
BST2 in human cells. The R44A:L45A mutation significantly impaired the ability of Vpu to reduce the 
amount of BST2 at the cell surface (Figure 7D). It also greatly impaired the ability of Vpu to enhance 
virion release (Figure 7E). Interestingly, the effect of the R44A:L45A mutation on virion release was 
additive with the S52/56N mutation, which ablates the binding of Vpu to β-TrCP (Figure 7E,G), despite 
that both mutations impair the apparent degradation of BST2 (Figure 7F). These data are consistent 
with the proposed role of R44 and I45 in the binding of Vpu to AP1 rather than to β-TrCP. Indeed, the 
R44A:L45A mutation did not affect the interaction with β-TrCP as measured by immunoprecipitation 
(Figure 7G). Together, the impaired abilities of Vpu R44A:L45A to bind AP1 and to decrease the 
steady-state expression of BST2 suggest that AP1 is important for the Vpu-mediated endo-lysosomal 
degradation of BST2.
We note that to achieve the interaction of R44, L/I45 with µ1 and the interaction of the ELV sequence 
with γ-σ1, VpuCD must adopt an extended conformation. Although observed with considerable helical 
content in previous NMR studies, VpuCD was believed to be flexible (Figure 7—figure supplement 1) 
(Willbold et al., 1997; Wittlich et al., 2009). Furthermore, these secondary structures were observed 
under conditions that induce helix formation. Specifically, the helical feature of the first half of VpuCD 
was shown to be relatively more pronounced, whereas the latter helix, harboring the ELV sequence, 
exhibited low helical content and was more likely to be unstructured (Wittlich et al., 2009). Our study 
provides further evidence for the flexible nature of VpuCD.
BST2 YxY and Vpu ELV motifs are both required for the optimal 
enhancement of virion release by Vpu and for the Vpu-mediated 
decrease in the expression of BST2
We performed virion release assays to confirm the functional requirements of the BST2 YxY and Vpu 
ELV motifs in human cells (Figure 8). The mutation Y6/8A in BST2CD markedly impaired the ability of 
Vpu to promote virion release, supporting a critical role for this trafficking motif in antagonism of BST2 
by Vpu. Since the BST2 YxY motif is not likely required for the β-TrCP-dependent degradation pathway, 
Figure 8. The BST2 YxY as well as the Vpu ELV and di-serine motifs are each important for Vpu-mediated reduction in BST2-expression and for optimal 
virion release. (A) HEK293T cells were co-transfected to express the indicated BST2 variants, provirus lacking vpu, and the indicated codon-optimized 
Vpu proteins. Mutations of the BST2 YxY, Vpu ELV and S52/S56 (‘2/6’) sequences have additive effects in decreasing the efficiency of Vpu mediated- 
virion release. (B) Western blot showing the expression levels of BST2 (WT or Y6/8A) and Vpu (WT or mutants).
DOI: 10.7554/eLife.02362.014
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which functions via ubiquitination, its importance likely comes from its affinity to AP1 and clathrin-
dependent pathways. Of note, the Y6/8A mutant was better expressed than wild-type BST2 and 
restricted virion release more effectively both in the presence and absence of Vpu. Alanine mutation 
of Vpu ELV also impaired virion release, to a degree similar to that of the S52/56N mutation of the 
β-TrCP binding site. Notably, mutation of the ELV sequence in Vpu and the YxY sequence in BST2 
increased the steady-state expression of BST2, presumably by inhibiting endo-lysosomal degradation 
either as it occurs natively or as stimulated by Vpu. This scenario is consistent with our structural and 
biochemical observations that both BST2 YxY and Vpu ELV motifs interact with AP1, and it further 
supports the hypothesis that this interaction is part of the endo-lysosomal degradation mechanism 
that supports Vpu-activity.
BST2 YxY and Vpu ELV motifs contribute to the co-localization of BST2 
and Vpu with AP1 at the cell center
We used immunofluorescence microscopy to verify the co-localization of BST2, Vpu and AP1 at the 
juxtanuclear region near the cell center (Figure 9; Figure 9—figure supplement 1). In HeLa cells that 
express BST2 constitutively, BST2 and AP1 co-localized even in the absence of Vpu, and all three 
proteins co-localized when Vpu was expressed (Figure 9—figure supplement 1). As expected, this 
co-localization was not affected by the Vpu S52/56N mutation, consistent with our in vitro observation 
that the β-TrCP binding motif of Vpu is not required for interaction with AP1. We further performed 
the immunofluorescence experiments after stably transfecting HT1080 cells to express BST2 (allowing 
the analysis of mutants since these cells do not naturally express BST2) followed by transient transfec-
tion to express Vpu. As was seen using the HeLa cells, BST2 and AP1 co-localized in the absence of 
Vpu, and all three proteins co-localized at the cell center when Vpu was expressed (Figure 9A). 
Mutation of the YxY sequence of BST2, and to a lesser extent the ELV sequence of Vpu, caused mislo-
calization of the proteins from the cell center region into more peripheral puncta, although some 
overlap at the cell center with AP1 persisted. Quantitative image analyses indicated that the YxY 
sequence of BST2 contributes to that protein's co-localization with AP1, as does the ELV sequence of 
Vpu (Figure 9B).
To clarify the role of these sequences in the trafficking of BST2–Vpu complexes, we analyzed the 
subcellular localization of our BST2–Vpu chimera that includes each protein's transmembrane domain 
(Figure 4B). This chimera has the advantage of ‘forcing’ the interaction between the two proteins, 
allowing the experiment to follow the fate of the chimera as a surrogate for BST2/Vpu complexes, 
without a potentially large background of the individual, uncomplexed proteins. The wild-type 
chimera localized to the cell center with AP1 as expected (Figure 9C). In contrast, the Y6/8A-ELV/AAA 
mutant colocalized less well with AP1; moreover, it was dispersed into peripheral endosomes and 
highlighted the plasma membrane. Correspondingly, enhanced surface expression was detected for 
the mutant chimera by flow cytometry (Figure 9D), indicating the loss of Vpu's ability to downregulate 
BST2 from the cell surface. Overall, these data support the proposed roles of the BST2 YxY and Vpu 
ELV sequences in the hijacking of AP1 by Vpu for the mistrafficking of BST2.
Discussion
Mistrafficking of host immune molecules via clathrin-dependent pathways is a strategy frequently 
employed by primate lentiviruses (Tokarev and Guatelli, 2011). For example, hijacking of AP-mediated 
trafficking pathways is well documented for the viral protein Nef (Piguet et al., 1999; Roeth and 
Collins, 2006; Arhel and Kirchhoff, 2009). Nef binds AP1 to prevent MHC-I from reaching the cell 
surface, providing evasion of immune surveillance by cytotoxic T cells (Collins et al., 1998; Le Gall 
et al., 1998; Roeth et al., 2004; Noviello et al., 2008). Nef also engages AP2 to remove the primary 
viral receptor, CD4, from cellular membranes to avoid super-infection, interference with virion release 
and infectivity, and the exposure on the cell surface of CD4-induced epitopes within the viral Env 
glycoprotein (Garcia and Miller, 1991; Foti et al., 1996; Craig et al., 1998; Chaudhuri et al., 2007; 
Veillette et al., 2013; Pham et al., 2014). In SIV, Nef uses AP2 to remove BST2 from the cell surface 
to allow for the efficient release of progeny virions (Zhang et al., 2011; Serra-Moreno et al., 2013). In 
addition, the HIV-2 Env protein antagonizes BST2 through an AP2-dependent mistrafficking mechanism 
(Hauser et al., 2010).
The work presented herein reveals that HIV-1 Vpu is another viral modulator of host membrane 
trafficking pathways, specifically, for the AP1-mediated mistrafficking of BST2. This is conceptually 
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Figure 9. YxY and ELV motifs contribute to BST2/Vpu/AP1 co-localization and the trafficking of BST2/Vpu complexes. (A) HT1080 cells stably expressing 
BST2 WT or the Y6/8A mutant were transfected to express Vpu or the ELV/AAA mutant. The cells were stained for Vpu, BST2, and AP1 (γ subunit). 
(B) Pearson co-efficient of correlation between AP1 and Vpu or between AP1 and BST2 vs the intensity of each protein. Each datum point represents a 
single cell. The correlation between Vpu and AP1 was analyzed in cells expressing wild type BST2, whereas that between BST2 and AP1 was analyzed in 
cells that were microscopically negative for Vpu expression (although transfected with the wild type Vpu-expression construct). Mutation of the YxY 
sequence in BST2 and the ELV sequence in Vpu decrease each protein's overlap with AP1. Statistical significance of these data is shown on the bottom. 
(C) HT1080 cell were transfected to express the BST2-Vpu chimera. The wild type chimera co-localized with AP1 at the perinuclear region. Alanine mutations 
of the YxY and ELV motifs decreased the co-localization of the BST2-Vpu chimera and AP1 and caused displacement of the chimera to peripheral 
endosomes and the plasma membrane. (D) The surface expression of the BST2-Vpu chimera after expression in HEK293T or HT1080 cells by transient 
transfection was measured using anti-FLAG antibody and flow cytometry. GFP was expressed from a separate plasmid as a transfection marker. The 
histograms show the cell number vs the intensity of surface stain for the chimera in the GFP-positive (transfected) cells. The Y6/8A mutation caused 
increased surface expression, as did the ELV/AAA mutation, although to a lesser extent. The highest expression at the cell surface was observed in case 
of the mutant containing both Y6/8A and ELV/AAA mutations.
DOI: 10.7554/eLife.02362.015
The following figure supplements are available for figure 9:
Figure supplement 1. Co-localization of BST2, Vpu, and AP1 in HeLa cells transfected to express either the wild type or the S52N/S56N mutant of Vpu. 
DOI: 10.7554/eLife.02362.016
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similar to the HIV-1 Nef-mediated MHC-I downregulation but occurs through different interaction 
mechanisms with AP1 (Figure 10). In each case, the HIV-1 protein, Nef or Vpu, causes the retention of 
its cellular target, MHC-I or BST2, at the TGN and eventually leads to lysosomal degradation through 
late endosomal pathways. Nef builds upon an incomplete tyrosine-based sorting motif in the MHC-I 
cytoplasmic domain (CD) and promotes a cooperative three-protein interaction involving MHC-I CD, 
Nef and μ1 of AP1 (Figure 10B) (Noviello et al., 2008; Wonderlich et al., 2008; Singh et al., 2009; 
Jia et al., 2012). The binding mode for the three-component complex involving BST2, Vpu and AP1, 
is different, with no three-protein interface. The complex is instead stabilized by pair-wise binary inter-
actions: BST2 and Vpu bind through the transmembrane regions, BST2CD binds the AP1 μ1 subunit, 
and VpuCD binds the AP1 σ1/γ/μ1 subunits (Figure 10A). This model is consistent with the previous 
findings that the transmembrane interaction between BST2 and Vpu is of pivotal importance in deter-
mining the activity of Vpu against BST2. The BST2/Vpu/AP1 interaction also causes an open confor-
mation of AP1 that has not been observed before. This new AP1 conformation might only be induced 
by Vpu or alternatively it might exist as a physiologically functional state that Vpu selectively uses to 
its advantage.
The Vpu-mediated antagonism of BST2 appears to be a multifaceted process. Besides AP1-
mediated mistrafficking and degradation, Vpu can also induce the degradation of BST2 through 
β-TrCP-mediated ubiquitination and the ESCRT machinery. Abolishing either the ubiquitination path-
way by the S52/56N mutation in Vpu or the mistrafficking pathway by the ELV/AAA mutation each led 
to defects in the enhancement of virion release (Figure 8) (Kueck and Neil, 2012; McNatt et al., 
2013). Combining the two sets of mutations, however, appeared to cause the most substantial loss 
of Vpu function, suggesting a potentially parallel nature for these pathways. How these pathways, 
ubiquitination and AP1-mediated mistrafficking, might work together to enable the antagonism of 
BST2 by Vpu remains to be further elucidated in finer temporal and spatial details.
The complexity of these trafficking and degradation mechanisms may have prevented a clear 
identification of the AP complex(es) responsible for the Vpu-activity in previous studies (Kueck and 
Neil, 2012). Despite the evidence supporting the involvement of clathrin-associated pathways, neither 
AP1, 2 or 3 knockdown in 293T cells and HeLa cells nor AP1 γ knockout in mouse fibroblasts had any 
apparent effects on the ability of Vpu to antagonize restriction by BST2 (Kueck and Neil, 2012), 
although we previously reported a role for AP2 in the Vpu-mediated surface-downregulation of BST2 
(Mitchell et al., 2009). Conceivably, the individual roles of a given pathway are obscured by compen-
sation from overlapping parallel pathways, such as the involvement of multiple AP complexes or the 
monomeric clathrin adaptor HRS. Another possibility is redundancy in the composition of an individual 
AP complex. A specific subunit of AP could be knocked down or out only to be replaced by a different 
isoform (Boehm and Bonifacino, 2001). Substitution might also happen between two related subunits 
Figure 10. Schematics of hijacking of AP1 by HIV-1 Vpu to target BST2 (left) and by HIV-1 Nef to target MHC-I (right) (Jia et al., 2012). Transmembrane 
helices are represented by cylinders and the Nef myristoyl anchor is represented by a cyan sphere.
DOI: 10.7554/eLife.02362.017
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from different AP complexes as they have highly conserved structures (Keyel et al., 2008; Li et al., 
2010). Another level of complexity might come from the potential for the mechanism of Vpu activity 
to be at least partly cell-type dependent. For example, BST2 in some cell types appears to be equally 
vulnerable to β-TrCP-dependent degradation and to mistrafficking, whereas in others the role of 
β-TrCP-dependent degradation is less important, possibly due to lower levels of BST2 expression 
(Schindler et al., 2010).
The intrinsic, structural flexibility of Vpu may enable its functional versatility and underlie the 
complexity of BST2-antagonism. A shared feature of retroviral accessory proteins including Vpu, Nef, 
Vif, Vpr and Vpx is the presence of long and flexible loops that provide the structural basis for their 
multifunctional nature (Xue et al., 2012). These unstructured regions can adopt different conformations 
to facilitate binding to different host target proteins. These regions often harbor motifs mimicking 
functional host sequences, enabling the virus to hijack the desired host machineries (Kadaveru et al., 
2008). The binding of the Vpu ELV motif to AP1 revealed in our structure, as well as that of the 
di-phosphoserine motif of Vpu to β-TrCP shown before, serve as two excellent examples of this viral 
strategy.
The ExxxLV motif is conserved in the Vpu of subtype B of group M HIV-1, to which both NL4-3 
and HV1S1 strains of HIV-1 used in this study belong. However, in the Vpu sequence from the 
subtype C of the group M HIV-1, the motif is replaced by the consensus sequence ExxxMV, which 
might or might not be functionally equivalent to the ExxxLV sequence. Interestingly, while subtype 
B Vpu localizes predominantly within internal membrane compartments, subtype C Vpu is substan-
tially expressed at the cell surface (Pacyniak et al., 2005). In addition to the sequence variation in 
the ELV region, subtype C Vpu contains another putative acidic dileucine motif in the membrane-
proximal region of its CD, mutation of which affected the trafficking of Vpu (Ruiz et al., 2008). 
Conceivably, subtype C Vpu hijacks AP complexes using residues distinct or partly overlapping with 
those used by subtype B Vpu.
The intrinsic affinity of Vpu to AP1 and AP2 suggests that Vpu has the ability to hijack clathrin-
dependent trafficking pathways to target other cellular proteins with which it interacts simultaneously. 
Besides BST2 and CD4, HIV-1 Vpu also modulates the surface expression of two other important 
immune factors, NTB-A and CD1d (Sandberg et al., 2012). NTB-A is a co-activator for natural killer (NK) 
cells, and the Vpu induced downregulation of NTB-A enables infected cells to evade lysis by NK cells 
(Shah et al., 2010). This involves the mistrafficking of NTB-A, which phenotypically resembles Vpu-
mediated BST2 mistrafficking (Bolduan et al., 2013). Although degradation is not induced, Vpu causes 
retention of NTB-A in a perinuclear compartment. Like BST2, the downregulation depends on an 
interaction between the transmembrane domains of Vpu and NTB-A (Shah et al., 2010). In addition, 
residues other than the conserved phosphorylated serines in VpuCD are critical (Bolduan et al., 2013). 
In the case of CD1d, an antigen-presenting molecule in dendritic cells, downregulation by Vpu occurs 
through interference with the recycling of CD1d in the endosomal compartments (Moll et al., 2010). 
A critical residue of CD1d, Tyr331 in a canonical sorting motif, is key for both the natural trafficking and 
the Vpu-mediated CD1d downregulation. Whether CD1d also interacts with Vpu in the transmem-
brane or other regions remains to be determined. Given the similarities between these systems, 
we speculate that the modulation of NTB-A and/or CD1d by Vpu may also involve clathrin-dependent 
trafficking pathways.
Finally, we consider the question of why BST2 interacts on its own with AP1, since this must relate 
in some way to the protein's natural function. One possibility is that the interaction with AP1 allows 
BST2 that is internalized from the cell surface to recycle to the plasma membrane, where it acts to trap 
nascent virions. Another possibility derives from the ability of BST2 to induce the activity of the NF-κB 
family of transcription factors (Cocka and Bates, 2012; Galao et al., 2012; Tokarev et al., 2013); this 
signaling function could occur from an endosomal compartment that BST2 reaches via AP1-dependent 
trafficking. Yet another possibility is that BST2 uses AP1 to divert tethered virions to late endosomal 
compartments in antigen presenting cells, thus facilitating the presentation of viral antigens in the 
context of class II or class I MHC (Neil et al., 2006; Miyakawa et al., 2009; Moffat et al., 2013). 
Whether these or other processes underlie the physiologically relevant function of the interaction 
between BST2 and AP1 remains to be determined.
In conclusion, our biochemical and biological data support, and our crystal structure elucidates 
in atomic detail, how HIV-1 Vpu hijacks the AP1-dependent membrane trafficking pathway to 
antagonize the host restriction factor BST2. These results not only help unravel the perplexing 
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mechanism of Vpu-mediated antagonism of BST2 but also suggest a potentially evolutionarily 
conserved function of Vpu in antagonizing other host immune targets. This function might be 
critical in understanding the full capacity of Vpu in promoting the infectivity and pathogenesis of 
the primate lentiviruses.
Materials and methods
Cloning, expression and purification of proteins used for in vitro 
studies
The BST2CD-VpuCD fusion consisted of BST2 (1-21) and Vpu (HV1S1, 28-80), connected by a linker pep-
tide of 10 amino acids: GSDEASEGSG. The encoding gene was cloned into the pMAT9s expression 
vector containing a N-terminal 6xHis tag followed by the maltose binding protein (MBP) and a SARS-
CoV Mpro cleavage site (Xue et al., 2007, 2008). To introduce phosphorylation on Vpu S52 and S56, 
this plasmid and a pCDFDuet vector encoding both the α and β subunits of the casein kinase II (CK2) 
were co-transformed into the E. coli NiCo21(DE3) competent cells (New England Biolabs) for expres-
sion in the Terrific broth. Cells were induced with 0.1 mM isopropyl β-d-thiogalactopyranoside (IPTG) 
at OD600 of 0.8 and grown at 16°C overnight. The protein was first purified with the Ni-NTA affinity 
column. For crystallization, the 6xHis-MBP tag was cleaved off by the SARS-CoV Mpro protease. Protein 
was subsequently purified on a HiTrap Q anion exchange column and a Superdex 75 size exclusion 
column, which yielded homogenous monomeric protein. Double phosphorylation of the protein 
was confirmed by using MALDI mass spectrometry. For GST pull-down experiments, the 6xHis-
MBP-tagged proteins, either wild-type or mutants, were purified through Ni-NTA, HiTrap Q and 
Superdex 200 size exclusion columns. The unphosphorylated form or the S52/56N (Vpu) mutant of 
the fusion was produced similarly except that the pCDFDuet-CK2 plasmid was not included during 
expression. 6xHis-MBP-VpuCD (phosphorylated) and 6xHis-MBP-BST2CD were expressed and purified 
similarly.
For the AP1 core used in the crystallization, the genes encoding residues 1-613 of mouse γ and 
1-158 of human σ1 were subcloned into the pCDFDuet vector, while genes encoding residues 
1-584 of human β1 and 1-423 of mouse μ1 were subcloned into the pETDuet vector. Non-cleavable 
6xHis tags were included at the N-termini of both the γ and β1 subunits. The heterotetrameric AP1 
core was expressed overnight at 22°C in the NiCo21(DE3) cells in Terrific broth after induction by 
0.1 mM IPTG. The complex was purified sequentially through Ni gravity, HiTrap Q, and Superdex 
200 size exclusion columns. The μ1-CTD-truncated AP1 core was created by introducing a stop 
codon after residue 145 of the μ1 subunit in the pCDFDuet vector carrying both the γ and μ1 
subunits. The truncated AP1 core was expressed and purified similarly. The AP1 core used in the 
GST pull-down experiments further included a GST tag at the C-terminus of the γ subunit. The 
AP1-GST complex was expressed similarly as above. The complex was purified by Ni gravity and 
GST columns, followed by buffer-exchange to remove the glutathione for its subsequent use in the 
GST pull-down assays.
MBP-μ1-CTD and MBP-μ2-CTD were created previously (Jia et al., 2012). MBP-μ3-CTD was 
created by subcloning the gene encoding residues 166-418 of rat μ3 into the pMAT9s expression 
vector. These proteins were overexpressed and purified as described previously (Jia et al., 2012). The 
hemicomplex of AP2, α398-σ, was created by subcloning the rat α (1-398, with three surface mutations 
I370A:I374S:L393A) and human σ into the pCDFDuet vector. The heterodimer was expressed similarly 
as the BST2CD-VpuCD fusion above and was purified sequentially on a Ni-NTA affinity column, a HiTrap 
S cation exchange column, and a Superdex 200 size exclusion column.
Crystallization and data collection
Crystallization was carried out using the microbatch under-oil method. The purified AP1 core and the 
BST2CD-VpuCD fusion were mixed at 1:3 molar ratio to a final concentration of 4.5 mg/ml (25 mM Tris, 
pH 8.0, 100 mM NaCl, 0.1 mM TCEP, 0.1 mM PMSF, 0.2 mM EDTA). Equal volumes of the protein 
solution and the precipitant solution (100 mM Tris, pH 7.0, 150 mM NaCl, 8% PEG6000) were mixed. 
The drop was sealed using a mixture of paraffin and silicon oil at a 2:1 ratio. Crystals appeared within 
24 hr at room temperature and grew to full size in about a week.
Crystals were cryo-protected using the precipitant solution containing 20% glycerol and then fro-
zen in liquid nitrogen. Datasets were collected at NE-CAT beamline 24ID-C at the Advanced Photon 
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Source, Argonne National Laboratory, and beamline X29 at the National Synchrotron Light Source, 
Brookhaven National Laboratory. The crystals were in the P43 space group and diffracted to a highest 
resolution of 3.0 Å. The data collection statistics are summarized in Table 1.
Structure determination and refinement
The structural solution was obtained by molecular replacement using PHASER (McCoy et al., 
2007) implemented in PHENIX (Adams et al., 2010). Only one molecule exists in the asymmetric 
unit. The structure of the closed AP1 core (PDB ID: 1W63) (Heldwein et al., 2004) was divided into 
three search models: the γ and σ1 hemicomplex, the β1 and μ1-NTD hemicomplex, and the μ1-CTD. 
These models were used in sequential searches to successfully obtain the solution. Iterative rounds 
of model building in COOT (Emsley et al., 2010) and refinement with PHENIX (Adams et al., 2010) 
were carried out. Data sharpening was performed to enhance the details in the electron density map 
(Liu and Xiong, 2013). BST2CD and VpuCD were built into the model based on the prominent differ-
ence densities at their corresponding locations. The final model has an Rwork/Rfree of 0.18/0.22. The 
refinement statistics are summarized in Table 1.
In vitro binding assays using size exclusion chromatography
The purified proteins, MBP-μ1/2/3-CTD (0.86 mg) or α398-σ (0.73 mg) and MBP-BST2CD/MBP-VpuCD 
(0.73 mg) or their mutants, were mixed to a final volume of 500 µl. Similarly, the μ1-CTD-truncated AP1 
(3.4 mg) and MBP-VpuCD (1.2 mg, wt or the ELV/AAA 
mutant) were mixed to a final volume of 500 µl. All sam-
ples were incubated overnight at 4°C and then applied 
to the Superdex 200 10/300 GL size exclusion column 
pre-equilibrated with the elution buffer (25 mM Tris, pH 
8, 100 mM NaCl, 0.1 mM TCEP). The elution fractions 
were analyzed by using SDS PAGE.
In vitro GST pulldown assays
The purified proteins, AP1-GST (0.24 mg) and MBP-
BST2CD-VpuCD/MBP-BST2CD/MBP-VpuCD (0.18 mg) or 
their mutants, were mixed in a final volume of 100 µl 
and incubated at 4°C overnight. The protein solution 
was then loaded onto a small gravity flow column 
containing 0.2 ml GST resin. Flow through was 
collected and the resin was extensively washed with 
5 × 0.9 ml GST binding buffer (50 mM Tris, pH 8, 100 mM 
NaCl, 0.1 mM TCEP). The bound proteins were then 
eluted with 5 × 0.1 ml GST elution buffer containing 
10 mM reduced glutathione. The eluted proteins 
were analyzed on SDS PAGE stained with Coomassie 
blue.
In vitro 6xHis pulldown assays
6xHis-MBP-μ1 (0.25 mg) and the BST2CD-VpuCD fusion 
(0.1 mg) or its mutants were mixed in a final volume of 
100 µl and incubated at 4°C for 2 hr. The proteins were 
loaded on a small gravity column containing 0.2 ml 
Ni-NTA resin. Flow through was collected and the resin 
was extensively washed with 5 × 0.9 ml binding buffer 
containing 20 mM imidazole. The bound proteins were 
subsequently eluted with 5 × 0.1 ml Ni elution buffer 
containing 400 mM imidazole. The eluted proteins were 
analyzed on SDS PAGE stained with Coomassie blue.
Yeast two-hybrid assays
AH109 yeast cells (Clontech Laboratories, Inc, Palo 
Alto, CA) were co-transformed to express both hybrid 
Table 1. Crystallographic data collection 
and refinement statistics
Native
Data collection
 Space group P43
 Cell dimensions
  a, b, c (Å) 160.5, 160.5, 118.4
 Wavelength (Å) 0.9792
 Resolution (Å) 48.8–3.0 (3.11–3.0)
 Rmerge 0.077
 I/σI 13.6 (0.9)
 Completeness (%) 99.4 (99.5)
 Redundancy 3.8 (3.7)
Refinement
 Unique reflections 59937
 Rwork/Rfree 0.186/0.229
 No. atoms
  Protein 13,926
  Water 14
 B-factors
  Protein 107.1
  Water 74.2
 R.m.s deviations
  Bond lengths (Å) 0.013
  Bond angles (°) 1.27
 Ramachandran
  Favored 95%
  Outliers 0.23%
Values in parenthesis are for highest-resolution 
shell.
DOI: 10.7554/eLife.02362.018
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proteins. The GAL4-Activation domain in pACT2 fused with the μ1 subunit was provided by Juan 
Bonifacino. The GAL4-DNA binding domain (DBD) in pGBT9 was fused to the BST2 cytoplasmic 
domain (CD) with the linker GGGSGGGSGGGS inserted between the BST2CD start codon and the DBD 
of the GAL4 protein. BST2CD was inserted between the EcoRI and SalI restriction sites of the pGBT9 
multiple cloning site. Yeast cells were transformed by the lithium-acetate method. Transformants were 
picked; colonies were pooled and grown in -Leu/-Trp liquid media before plating as spots on -Leu/-Trp 
solid media as a growth control or on -Trp/-Leu/-His solid media containing 3-aminotriazole (3AT) to 
test for interaction.
Virion release assays
For the virion release assays, the following plasmids were used: the proviral Vpu-mutant pNL43/Udel 
(Klimkait et al., 1990); pcDNA3.1-BST-2 from Autumn Ruiz and Edward Stephens; pcDNA3.1-BST2-
Y6/8A constructed by site-directed mutagenesis of pcDNA3.1-BST2 using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA); pVpHu-FLAG constructed by cloning the 
codon-optimized Vpu sequence from pVpHu (from Klaus Strebel) with primers introducing a C-terminal 
FLAG tag (DYKDDDDK) into the NheI and XhoI sites of the pcDNA3.1(−) vector (Life Technologies, 
Carlsbad, CA); and the FLAG-tagged Vpu-mutant expression plasmids pVpHu-FLAG-S52/56N, pVpHu-
FLAG-ELV59,63,64AAA and pVpHu-FLAG-S52/56N + ELV/AAA constructed by site-directed muta-
genesis of pVpHu-FLAG using QuikChange (Stratagene).
HEK293T cells in six-well plates were transfected using Lipofectamine 2000 (Life Technologies, 
Carlsbad, CA) with 50 ng of the indicated BST2 expression plasmid, 250 ng of the indicated VpHu-
FLAG expression plasmid and 3600 ng of the Vpu-mutant proviral plasmid pNL43/Udel. Supernates 
were collected 24 hr after transfection as previously described (Van Damme et al., 2008). Virion-
associated p24 was pelleted through a 20% sucrose cushion before measurement by p24 ELISA 
(Advanced Bioscience Laboratories, Rockville, MD). Cells were harvested and lysed 24 hr post-
transfection and immunoblots for BST2, gp120, actin, and FLAG-epitope were performed as previ-
ously described (Day et al., 2004; Tokarev and Guatelli, 2011; Tokarev et al., 2013).
Co-immunoprecipitation assays
293T cells were transfected with the plasmids expressing the constructs indicated in the figure leg-
ends, using Lipofectamine 2000 and the manufacturer's protocol. The next day, cells were lysed in lysis 
buffer (50 mM Tris HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and 5% glycerol) supple-
mented with protease inhibitors cocktail (Roche Diagnostics). Lysates were cleared by centrifugation 
for 10 min at 16,000×g and incubated with magnetic anti-FLAG-coated beads for BST2, Vpu or the 
BST2-Vpu chimera; or with anti-HA-coated beads for β-TrCP, which were pre-blocked with 3% BSA in 
PBS, for 2 hr at 4°C with continuous rotation. Beads were washed three times with lysis buffer contain-
ing 250 mM NaCl. The precipitated material was eluted with boiling in 2x Laemmli buffer and sub-
jected to Western blotting. Endogenous µ1 was detected using a rabbit antiserum provided by Linton 
Traub.
Immunofluorescence assays
HeLa P4R5 or HT1080 cells were transfected with Vpu or BST2-Vpu chimera constructs, as indi-
cated in the figure legends, using Lipofectamine 2000. The next day, cells were fixed with 4% para-
formaldehyde, permeabilized with 0.2% NP-40, blocked with PBS containing 5% donkey serum, 
5% goat serum (Jackson Immunoresearch) and 3% BSA. For Figure S6, cells were first stained with 
mouse anti-γ adaptin (clone 100/3, Sigma-Aldrich) and anti-Vpu rabbit serum, washed three times 
with PBS and stained with anti-rabbit antibody conjugated to rhodamine red-X and anti-mouse 
antibody conjugated to FITC (Jackson Immunoresearch). Cells were then blocked with 5% mouse 
serum and stained with mouse anti-BST2 conjugated to Alexa Fluor 647 (Biolegend, San Diego 
CA). For Figure 9A, the staining was performed as just described, except that the secondary 
antibody to detect Vpu was anti-rabbit conjugated to FITC and the secondary antibody to detect 
AP1 was anti-mouse conjugated to rhodamine red-X. For Figure 9C, the chimeras were visualized 
using anti-Vpu rabbit serum, and AP1 was visualized using mouse anti-γ adaptin. The secondary 
antibodies used were anti-mouse conjugated to FITC and anti-rabbit conjugated to rhodamine 
red-X. After staining, cells were washed, fixed again, and mounted in solid media (Fluka). Images were 
acquired as Z-series using an Olympus microscope in wide-field mode. Images were deconvolved 
using a nearest neighbors method (SlideBook software, Intelligent Imaging Innovations, Denver, 
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CO) and the Z-series were collapsed into single projection images. Co-localization was quantified 
using the Pearson correlation coefficient function in SlideBook. T-values were calculated using 
Microsoft Excel. Composite images were generated using Adobe Photoshop.
Flow cytometry
Two-color flow cytometry was performed on unpermeabilized cells using an Accuri C6 flow cytometer 
to measure the intensity of GFP and the FLAG-epitope, which was detected indirectly using murine 
anti-FLAG (Sigma-Aldrich) followed by allophycocyanin (APC)-conjugated anti-mouse antibody 
(Biolegend, San Diego, CA).
Acknowledgements
We thank Mark Skasko for the initial design and functional characterization of the RL/AA mutant. We 
thank the staff at the Advanced Photon Source beamline 24-ID and the National Synchrotron Light 
Source beamline X29. We thank Juan Bonifacino for providing the genes of AP complexes, Linton 
Traub for providing the rabbit antiserum to µ1, and Olaf-Georg Issinger for providing the CKII genes. 
We thank Suresh Subramani for providing the AH109 yeast cells. Rabbit antisera to BST2 and Vpu were 
obtained from the NIH AIDS Reagent Program and contributed by Klaus Strebel. This work was 
supported by US National Institutes of Health (NIH) grants AI102778 (YX and JG), AI097064 (YX), 
AI081668 (JG) as well as by The James B Pendleton Charitable Trust. MR was supported in part by the 
San Diego Fellowship. AT was supported in part by AI007384 (T32 AIDS Training Grant).
Additional information
Funding
Funder
Grant reference  
number Author
National Institutes of Health AI102778 John Guatelli,  
Yong Xiong
The James B. Pendleton Charitable Trust John Guatelli
The San Diego Fellowship Maryan Rizk
National Institutes of Health AI097064 Yong Xiong
National Institutes of Health AI081668 John Guatelli
National Institutes of Health AI007384 Andrey Tokarev
The funders had no role in study design, data collection and interpretation, or the  
decision to submit the work for publication.
Author contributions
XJ, EW, AT, ML, MR, MS, Conception and design, Acquisition of data, Analysis and interpretation of 
data, Drafting or revising the article; JG, YX, Conception and design, Analysis and interpretation of 
data, Drafting or revising the article
Additional files
Major datasets
The following datasets were generated:
Author(s) Year Dataset title Dataset ID and/or URL
Database, license,  
and accessibility  
information
Jia X,  Xiong Y 2014 Crystal structure of the human  
BST2 cytoplasmic domain and  
the HIV-1 Vpu cytoplasmic  
domain bound to the clathrin  
adaptor protein complex 1 (AP1)  
core
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=4P6Z
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Biophysics and structural biology | Microbiology and infectious disease
Jia et al. eLife 2014;3:e02362. DOI: 10.7554/eLife.02362 20 of 24
Research article
The following previously published datasets were used:
Author(s) Year Dataset title Dataset ID and/or URL
Database, license,  
and accessibility  
information
Heldwein E,  Macia E,   
Wang J,  Yin HL,   
Kirchhausen T,   
Harrison SC
2004 AP1 clathrin adaptor core http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=1W63
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Owen DJ,  Mccoy AJ,   
Kelly BT,  Evans PR
2008 AP2 clathrin adaptor corewith  
CD4 Dileucine peptide  
RM(phosphoS) EIKRLLSE  
Q to E mutant
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=2jkt
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Ren X,  Farias GG,   
Canagarajah BJ,   
Bonifacino JS,   
Hurley JH
2013 Structural basis for recruitment  
and activation of the AP-1 clathrin  
adaptor complex by Arf1
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=4hmy
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Owen DJ,  Evans PR 1998 Mu2 adaptin subunit (AP50) of  
AP2 adaptor (second domain),  
complexed with TGN38  
internalization peptide dyqrln
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=1bxx
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Mardones GA,   
Kloer DP,  Burgos PV,   
Bonifacino JS,   
Hurley JH
2012 Crystal structure of adaptor  
protein complex 3 (AP-3) mu3A  
subunit C-terminal domain, in  
complex with a sorting peptide  
from TGN38
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=4ikn
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Willbold D,   
Hoffmann S,   
Rosch P
1997 NMR solution structure of the  
HIV-1 Vpu cytoplasmic domain,  
9 structures
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=1vpu
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
Wittlich M,   
Koenig BW,   
Willbold D
2008 Solution fold of HIV-1 Virus  
protein U cytoplasmic domain  
in the presence of DPC micelles
http://www.rcsb.org/ 
pdb/explore/explore. 
do?structureId=2k7y
Publicly available at the  
RCSB Protein Data Bank 
(http://www.rcsb.org/).
References
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ,  
Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, 
Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta 
Crystallographica Section D-Biological Crystallography 66:213–221. doi: 10.1107/S0907444909052925.
Andrew AJ, Miyagi E, Strebel K. 2011. Differential effects of human immunodeficiency virus type 1 Vpu on the 
stability of BST-2/Tetherin. Journal of Virology 85:2611–2619. doi: 10.1128/JVI.02080-10.
Arhel NJ, Kirchhoff F. 2009. Implications of Nef: host cell interactions in viral persistence and progression to AIDS. 
Current Topics in Microbiology and Immunology 339:147–175. doi: 10.1007/978-3-642-02175-6_8.
Arias JF, Iwabu Y, Tokunaga K. 2012. Sites of Action of HIV-1 Vpu in BST-2/Tetherin Downregulation. Current HIV 
Research 10:283–291. doi: 10.2174/157016212800792423.
Boehm M, Bonifacino JS. 2001. Adaptins - the final recount. Molecular Biology of the Cell 12:2907–2920. 
doi: 10.1091/mbc.12.10.2907.
Bolduan S, Hubel P, Reif T, Lodermeyer V, Hohne K, Fritz JV, Sauter D, Kirchhoff F, Fackler OT, Schindler M, 
Schubert U. 2013. HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A. Virology 
440:190–203. doi: 10.1016/j.virol.2013.02.021.
Bonifacino JS, Traub LM. 2003. Signals for sorting of transmembrane proteins to endosomes and lysosomes. 
Annual Review of Biochemistry 72:395–447. doi: 10.1146/annurev.biochem.72.121801.161800.
Canagarajah BJ, Ren XF, Bonifacino JS, Hurley JH. 2013. The clathrin adaptor complexes as a paradigm for 
membrane-associated allostery. Protein Science 22:517–529. doi: 10.1002/pro.2235.
Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS. 2007. Downregulation of CD4 by human 
immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 
clathrin adaptor. Journal of Virology 81:3877–3890. doi: 10.1128/JVI.02725-06.
Cocka LJ, Bates P. 2012. Identification of alternatively translated Tetherin isoforms with differing antiviral and 
signaling activities. PLOS Pathogens 8:e1002931. doi: 10.1371/journal.ppat.1002931.
Cohen EA, Terwilliger EF, Sodroski JG, Haseltine WA. 1988. Identification of a protein encoded by the Vpu gene 
of Hiv-1. Nature 334:532–534. doi: 10.1038/334532a0.
Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. 1998. HIV-1 Nef protein protects infected primary cells 
against killing by cytotoxic T lymphocytes. Nature 391:397–401. doi: 10.1038/34929.
Craig HM, Pandori MW, Guatelli JC. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting 
pathway is required for CD4 down-regulation and optimal viral infectivity. Proceedings of the National Academy 
of Sciences of the United States of America 95:11229–11234. doi: 10.1073/pnas.95.19.11229.
Biophysics and structural biology | Microbiology and infectious disease
Jia et al. eLife 2014;3:e02362. DOI: 10.7554/eLife.02362 21 of 24
Research article
Day JR, Munk C, Guatelli JC. 2004. The membrane-proximal tyrosine-based sorting signal of human immunodefi-
ciency virus type 1 gp41 is required for optimal viral infectivity. Journal of Virology 78:1069–79.
Douglas JL, Viswanathan K, Mccarroll MN, Gustin JK, Fruh K, Moses AV. 2009. Vpu directs the degradation of the 
human immunodeficiency virus restriction factor BST-2/Tetherin via a beta TrCP-dependent mechanism. Journal 
of Virology 83:7931–7947. doi: 10.1128/JVI.00242-09.
Dube M, Paquay C, Roy BB, Bego MG, Mercier J, Cohen EA. 2011. HIV-1 Vpu antagonizes BST-2 by interfering 
mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 12:1714–1729.
Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A, Cohen EA. 2010. Antagonism of Tetherin 
restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear 
compartment. Plos Pathogens 6:e1000856. doi: 10.1371/journal.ppat.1000856.
Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, Cohen A. 2009. Suppression of Tetherin-
restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of 
Vpu in the trans-Golgi network. Journal of Virology 83:4574–4590. doi: 10.1128/JVI.01800-08.
Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallographica 
Section D-Biological Crystallography 66:486–501. doi: 10.1107/S0907444910007493.
Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. 2010. BST-2/tetherin: a new component of the innate immune 
response to enveloped viruses. Trends in Microbiology 18:388–396. doi: 10.1016/j.tim.2010.06.010.
Foti M, Mangasarian A, Piguet V, Lew DP, Krause KH, Trono D, Carpentier JL. 1997. Nef-mediated clathrin-coated 
pit formation. The Journal of Cell Biology 139:37–47. doi: 10.1083/jcb.139.1.37.
Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. 2012. Innate sensing of HIV-1 assembly by Tetherin induces 
NFkappaB-dependent proinflammatory responses. Cell Host Microbe 12:633–44. doi: 10.1016/j.chom.2012.10.007.
Garcia JV, Miller AD. 1991. Serine phosphorylation-independent down-regulation of cell-surface Cd4 by Nef. 
Nature 350:508–511. doi: 10.1038/350508a0.
Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, 
Krijnse-Locker J, Banting G, Kräusslich HG, Fackler OT, Keppler OT. 2009. HIV-1 antagonism of CD317 is 
species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host & Microbe 
5:285–297. doi: 10.1016/j.chom.2009.01.009.
Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT. 2010. Antagonism of CD317 restriction 
of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities 
of HIV-1 Vpu. Journal of Virology 84:4089–4094. doi: 10.1128/JVI.01549-09.
Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. 2010. HIV-1 Vpu and HIV-2 
Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51.  
doi: 10.1186/1742-4690-7-51.
Heldwein EE, Macia E, Jing W, Yin HL, Kirchhausen T, Harrison SC. 2004. Crystal structure of the clathrin adaptor 
protein 1 core. Proceedings of the National Academy of Sciences of the United States of America 101:14108–14113. 
doi: 10.1073/pnas.0406102101.
Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, Renesto P, Hartlieb B, McCarthy AA, Simorre JP, Göttlinger 
H, Weissenhorn W. 2010. Structural basis of HIV-1 tethering to membranes by the BST-2/Tetherin ectodomain. 
Cell Host & Microbe 7:314–323. doi: 10.1016/j.chom.2010.03.005.
Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K. 2009. HIV-1 accessory protein 
Vpu internalizes cell-surface BST-2/Tetherin through transmembrane interactions leading to lysosomes. Journal 
of Biological Chemistry 284:35060–35072. doi: 10.1074/jbc.M109.058305.
Iwabu Y, Fujita H, Tanaka Y, Sata T, Tokunaga K. 2010. Direct internalization of cell-surface BST-2/tetherin by the 
HIV-1 accessory protein Vpu. Communicative & Integrative Biology 3:366–369. doi: 10.4161/cib.3.4.11971.
Jackson LP, Kelly BT, Mccoy AJ, Gaffry T, James LC, Collins BM, Höning S, Evans PR, Owen DJ. 2010. A 
large-scale conformational change couples membrane recruitment to cargo binding in the AP2 clathrin adaptor 
complex. Cell 141:1220–1229. doi: 10.1016/j.cell.2010.05.006.
Janvier K, Pelchen-Matthews A, Renaud JB, Caillet M, Marsh M, Berlioz-Torrent C. 2011. The ESCRT-0 component 
hrs is required for HIV-1 vpu-mediated BST-2/Tetherin down-regulation. PLOS Pathogens 7:e1001265.  
doi: 10.1371/journal.ppat.1001265.
Jia XF, Singh R, Homann S, Yang HT, Guatelli J, Xiong Y. 2012. Structural basis of evasion of cellular adaptive 
immunity by HIV-1 Nef. Nature Structural & Molecular Biology 19:701–706. doi: 10.1038/nsmb.2328.
Jouvenet N, Neil SJD, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. 
Broad-spectrum inhibition of retroviral and Filoviral particle release by tetherin. Journal of Virology 83:1837–1844. 
doi: 10.1128/JVI.02211-08.
Kadaveru K, Vyas J, Schiller MR. 2008. Viral infection and human disease–insights from minimotifs. Frontiers in 
Bioscience: a Journal and Virtual Library 13:6455–6471. doi: 10.2741/3166.
Kelly BT, Mccoy AJ, Spate K, Miller SE, Evans PR, Honing S, Owen DJ. 2008. A structural explanation for the 
binding of endocytic dileucine motifs by the AP2 complex. Nature 456:976–979. doi: 10.1038/nature07422.
Keyel PA, Thieman JR, Roth R, Erkan E, Everett ET, Watkins SC, Heuser JE, Traub LM. 2008. The AP-2 adaptor 
beta 2 appendage scaffolds alternate cargo endocytosis. Molecular Biology of the Cell 19:5309–5326.  
doi: 10.1091/mbc.E08-07-0712.
Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. 1990. The human immunodeficiency virus type 
1-specific protein vpu is required for efficient virus maturation and release. Journal of Virology 64:621–629.
Kobayashi T, Ode H, Yoshida T, Sato K, Gee P, Yamamoto SP, Ebina H, Strebel K, Sato H, Koyanagi Y. 2011. 
Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction 
and susceptibility. Journal of Virology 85:932–945. doi: 10.1128/JVI.01668-10.
Biophysics and structural biology | Microbiology and infectious disease
Jia et al. eLife 2014;3:e02362. DOI: 10.7554/eLife.02362 22 of 24
Research article
Kueck T, Neil SJD. 2012. A cytoplasmic tail determinant in HIV-1 vpu mediates targeting of tetherin for endosomal 
degradation and counteracts interferon-induced restriction. Plos Pathogens 8:e1002609. doi: 10.1371/journal.
ppat.1002609.
Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. 2003. BST-2/HM1.24 is a raft-associated 
apical membrane protein with an unusual topology. Traffic [traffic (copenhagen, Denmark)] 4:694–709.  
doi: 10.1034/j.1600-0854.2003.00129.x.
Lau D, Kwan W, Guatelli J. 2011. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral 
pathogens. Journal of Virology 85:9834–9846. doi: 10.1128/JVI.02633-10.
Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L X, Benarous R, Heard JM, Schwartz O. 1998. Nef 
interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I 
molecules. Immunity 8:483–495. doi: 10.1016/S1074-7613(00)80553-1.
Li W, Puertollano R, Bonifacino JS, Overbeek PA, Everett ET. 2010. Disruption of the murine Ap2 beta 1 gene 
causes Nonsyndromic Cleft Palate. Cleft Palate-Craniofacial Journal 47:566–573. doi: 10.1597/09-145.
Liu C, Xiong Y. 2013. Electron density sharpening as a general technique in crystallographic studies. Journal of 
Molecular Biology 426:980–993. Epub ahead of print. doi: 10.1016/j.jmb.2013.11.014.
Lucas TM, Janaka SK, stephens EB, Johnson MC. 2012. Vpu downmodulates two distinct targets, tetherin and 
gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail. PLOS ONE 7:e51741. 
doi: 10.1371/journal.pone.0051741.
Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. 2009. HIV-1 vpu neutralizes the antiviral 
factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLOS Pathogens 
5:e1000574. doi: 10.1371/journal.ppat.1000574.
Mardones GA, Burgos PV, Lin Y, Kloer DP, Magadan JG, Hurley J H, Bonifacino JS. 2013. Structural basis for the 
recognition of tyrosine-based sorting signals by the mu 3A subunit of the AP-3 adaptor complex. Journal of 
Biological Chemistry 288:9563–9571. doi: 10.1074/jbc.M113.450775.
Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J, Tanaka Y. 2009. 
HM1.24 is internalized from lipid Rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. 
Journal of Biological Chemistry 284:15927–15941. doi: 10.1074/jbc.M109.005124.
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic 
software. Journal of applied crystallography 40:658–674. doi: 10.1107/S0021889807021206.
McNatt MW, Zang T, Bieniasz PD. 2013. Vpu binds directly to tetherin and displaces it from nascent virions. 
PLOS Pathogens 9:e1003299. doi: 10.1371/journal.ppat.1003299.
McNatt MW, Zang T, Hatziioannou T, Bartlett M, Ben Fofana I, Johnson WE, Neil SJ, Bieniasz PD. 2009. 
Species-specific activity of HIV-1 vpu and positive selection of tetherin transmembrane domain variants. 
PLOS Pathogens 5:e1000300. doi: 10.1371/journal.ppat.1000300.
Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, 
Guatelli JC. 2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal 
trafficking. PLOS Pathogens 5:e1000450. doi: 10.1371/journal.ppat.1000450.
Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, Yamamoto N. 2009. BCA2/Rabring7 
promotes tetherin-dependent HIV-1 restriction. PLOS Pathogens 5:e1000700. doi: 10.1371/journal.ppat.1000700.
Moffat JM, Segura E, Khoury G, Caminschi I, Cameron PU, Lewin SR, Villadangos JA, Mintern JD. 2013. 
Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells 
elicits efficient antigen presentation. European Journal of Immunology 43:595–605. doi: 10.1002/eji.201242799.
Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK. 2010. Inhibition of lipid antigen presentation in dendritic 
cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 116:1876–1884. 
doi: 10.1182/blood-2009-09-243667.
Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD. 2006. HIV-1 Vpu promotes release and prevents endocytosis of 
nascent retrovirus particles from the plasma membrane. PLOS Pathogens 2:e39. doi: 10.1371/journal.ppat.0020039.
Neil SJD, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 
451:425–430. doi: 10.1038/nature06553.
Noviello CM, Benichou S, Guatelli JC. 2008. Cooperative binding of the class I major histocompatibility complex 
cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu 
subunit. Journal of Virology 82:1249–1258. doi: 10.1128/JVI.00660-07.
Ohno H, Aguilar RC, Yeh D, Taura D, Saito T, Bonifacino JS. 1998. The medium subunits of adaptor complexes 
recognize distinct but overlapping sets of tyrosine-based sorting signals. Journal of Biological Chemistry 
273:25915–25921. doi: 10.1074/jbc.273.40.25915.
Owen DJ, Evans PR. 1998. A structural explanation for the recognition of tyrosine-based endocytotic signals. 
Science 282:1327–1332. doi: 10.1126/science.282.5392.1327.
Pacyniak ML, Gomez LM, Gomez ER, Mulcahy M, Jackson DR, Hout DR, Wisdom BJ, Stephens EB. 2005. 
Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodefi-
ciency virus type 1 (HIV-1) that is responsible for retention in the Golgi complex and its absence in the Vpu protein 
from a subtype CHIV-1. AIDS Research and Human Retroviruses 21:379–394. doi: 10.1089/aid.2005.21.379.
Pham TN, Lukhele S, Hajjar F, Routy JP, Cohen EA. 2014. HIV Nef and Vpu protect HIV-infected CD4+ T cells 
from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology 11:15.  
doi: 10.1186/1742-4690-11-15.
Pickering S, Hue S, Kim EY, Reddy S, Wolinsky SM, Neil SJ. 2014. Preservation of tetherin and CD4 counter-activities 
in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLOS Pathogens 
10:e1003895. doi: 10.1371/journal.ppat.1003895.
Biophysics and structural biology | Microbiology and infectious disease
Jia et al. eLife 2014;3:e02362. DOI: 10.7554/eLife.02362 23 of 24
Research article
Piguet V, Schwartz O, Le Gall S, Trono D. 1999. The downregulation of CD4 and MHC-I by primate lentiviruses: a 
paradigm for the modulation of cell surface receptors. Immunological Reviews 168:51–63. doi: 10.1111/j.1600-
065X.1999.tb01282.x.
Ren XF, Farias GG, Canagarajah BJ, Bonifacino JS, Hurley JH. 2013. Structural basis for recruitment and 
activation of the AP-1 clathrin adaptor complex by Arf1. Cell 152:755–767. doi: 10.1016/j.cell.2012.12.042.
Roeth JF, Collins KL. 2006. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking 
pathways. Microbiology and Molecular Biology Reviews 70:548–563. doi: 10.1128/MMBR.00042-05.
Roeth JF, Williams M, Kasper MR, Filzen TM, Collins KL. 2004. HIV-1 Nef disrupts MHC-1 trafficking by recruiting 
AP-1 to the MHC-1 cytoplasmic tail. Journal of Cell Biology 167:903–913. doi: 10.1083/jcb.200407031.
Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. 2007. Clathrin-mediated endocytosis of a lipid-raft-
associated protein is mediated through a dual tyrosine motif. Journal of Cell Science 120:3850–3858.  
doi: 10.1242/jcs.003343.
Ruiz A, Hill MS, Schmitt K, Guatelli J, Stephens EB. 2008. Requirements of the membrane proximal tyrosine and 
dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane 
and in virus release. Virology 378:58–68. doi: 10.1016/j.virol.2008.05.022.
Sandberg JK, Andersson SK, Bachle SM, Nixon DF, Moll M. 2012. HIV-1 vpu interference with innate cell-mediated 
immune mechanisms. Current HIV Research 10:327–333. doi: 10.2174/157016212800792513.
Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A, Specht A, Sauter D, Dobner T, 
Kirchhoff F. 2010. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in 
macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 7:1. doi: 10.1186/1742-4690-7-1.
Schmidt S, Fritz J, Bitzegeio J, Fackler O, Keppler O. 2011. HIV-1 vpu blocks recycling and biosynthetic transport 
of the intrinsic immunity factor CD317/Tetherin to overcome the virion release restriction. Mbio 2:e00036–11. 
doi: 10.1128/mBio.00036-11.
Schubert HL, Zhai QT, Sandrin V, Eckert DM, Garcia-Maya M, Saul L, Sundquist WI, Steiner RA, Hill CP. 2010. 
Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized 
conformations. Proceedings of the National Academy of Sciences of the United States of America 107:17951–17956. 
doi: 10.1073/pnas.1008206107.
Serra-Moreno R, Zimmermann K, Stern LJ, Evans DT. 2013. Tetherin/BST-2 antagonism by nef depends on a 
direct physical interaction between nef and tetherin, and on clathrin-mediated endocytosis. PLOS Pathogens 
9:e1003487. doi: 10.1371/journal.ppat.1003487.
Shah AH, Sowrirajan B, Davis ZB, Ward JP, Campbell EM, Planelles V, Barker E. 2010. Degranulation of natural 
killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-a by vpu. 
Cell Host & Microbe 8:397–409. doi: 10.1016/j.chom.2010.10.008.
Singh RK, Lau D, Noviello CM, Ghosh P, Guatelli JC. 2009. An MHC-I cytoplasmic domain/HIV-1 nef fusion 
protein binds directly to the mu subunit of the AP-1 endosomal Coat complex. PLOS ONE 4:e8364.  
doi: 10.1371/journal.pone.0008364.
Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, Stephens EB, Opella SJ, Guatelli J. 2012. HIV-1 vpu 
protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. Journal of 
Biological Chemistry 287:58–67. doi: 10.1074/jbc.M111.296772.
Strebel K, Klimkait T, Martin MA. 1988. A novel gene of Hiv-1, vpu, and its 16-Kilodalton product. Science 
241:1221–1223. doi: 10.1126/science.3261888.
Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT. 2011. beta-TrCP is dispensable for Vpu's 
ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release. Retrovirology 8:9.  
doi: 10.1186/1742-4690-8-9.
Tokarev A, Guatelli J. 2011. Misdirection of membrane trafficking by HIV-1 Vpu and Nef: keys to viral virulence 
and persistence. Cell Logist 1:90–102. doi: 10.4161/cl.1.3.16708.
Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. 2013. Stimulation of NF-kappa B activity by the 
HIV restriction factor BST2. Journal of Virology 87:2046–2057. doi: 10.1128/JVI.02272-12.
Traub L. 2009. Tickets to ride: selecting cargo for clathrin-regulated internalization. Nature Reviews Molecular 
Cell Biology 10:583–596. doi: 10.1038/nrm2751.
Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. 
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the 
viral Vpu protein. Cell Host & Microbe 3:245–252. doi: 10.1016/j.chom.2008.03.001.
Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, 
Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J, Finzi A. 2013. Interaction with cellular CD4 
exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. Journal of 
Virology 88:2633–2644. doi: 10.1128/JVI.03230-13.
Vigan R, Neil SJD. 2010. Determinants of tetherin antagonism in the transmembrane domain of the human 
immunodeficiency virus type 1 vpu protein. Journal of Virology 84:12958–12970. doi: 10.1128/JVI.01699-10.
Vigan R, Neil SJD. 2011. Separable determinants of subcellular localization and interaction account for the 
inability of group O HIV-1 vpu to counteract tetherin. Journal of Virology 85:9737–9748.
Willbold D, Hoffmann S, Rosch P. 1997. Secondary structure and tertiary fold of the human immunodeficiency 
virus protein U (Vpu) cytoplasmic domain in solution. European Journal of Biochemistry 245:581–588.  
doi: 10.1111/j.1432-1033.1997.t01-1-00581.x.
Wittlich M, Koenig BW, Stoldt M, Schmidt H, Willbold D. 2009. NMR structural characterization of HIV-1 virus 
protein U cytoplasmic domain in the presence of dodecylphosphatidylcholine micelles. The FEBS journal 
276:6560–6575. doi: 10.1111/j.1742-4658.2009.07363.x.
Biophysics and structural biology | Microbiology and infectious disease
Jia et al. eLife 2014;3:e02362. DOI: 10.7554/eLife.02362 24 of 24
Research article
Wonderlich ER, Williams M, Collins KL. 2008. The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu 1 
subunit is necessary for nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. 
Journal of Biological Chemistry 283:3011–3022. doi: 10.1074/jbc.M707760200.
Xue B, Mizianty MJ, Kurgan L, Uversky VN. 2012. Protein intrinsic disorder as a flexible armor and a weapon of 
HIV-1. Cellular and Molecular Life Sciences 69:1211–1259. doi: 10.1007/s00018-011-0859-3.
Xue XY, Yang HT, Shen W, Zhao Q, Li J, Yang KL, Chen C, Jin Y, Bartlam M, Rao Z. 2007. Production of authentic 
SARS-CoV M-pro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein 
overproduction. Journal of Molecular Biology 366:965–975. doi: 10.1016/j.jmb.2006.11.073.
Xue XY, Yu HW, Yang HT, Xue F, Wu ZX, Shen W, Li J, Zhou Z, Ding Y, Zhao Q, Zhang XC, Liao M, Bartlam M, Rao Z. 
2008. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug 
design. Journal of Virology 82:2515–2527. doi: 10.1128/JVI.02114-07.
Yang HT, Wang JM, Jia XF, Mcnatt MW, Zang T, Pan BC, Meng W, Wang HW, Bieniasz PD, Xiong Y. 2010. 
Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proceedings of the National 
Academy of Sciences of the United States of America 107:18428–18432. doi: 10.1073/pnas.1011485107.
Zhang FW, Landford WN, Ng M, Mcnatt MW, Bieniasz PD, Hatziioannou T. 2011. SIV nef proteins recruit the 
AP-2 complex to antagonize tetherin and facilitate virion release. PLOS Pathogens 7:e1002039. doi: 10.1371/
journal.ppat.1002039.
